Modality
Bispecific Ab
MOA
FcRni
Target
APOC3
Pathway
Cell Cycle
MDDIgANThymoma
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
Jan 2019
→ Apr 2031
Phase 2Current
NCT03272473
2,506 pts·MDD
2019-01→2025-10·Terminated
NCT07851470
267 pts·Thymoma
2019-06→2031-04·Completed
2,773 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-036mo agoPh2 Data· MDD
2031-04-075.0y awayPh2 Data· Thymoma
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2025-10-03 · 6mo ago
MDD
Ph2 Data
2031-04-07 · 5.0y away
Thymoma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03272473 | Phase 2 | MDD | Terminated | 2506 | 6MWD |
| NCT07851470 | Phase 2 | Thymoma | Completed | 267 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 |